Predictive value of ACR core set parameters for the development of rheumatoid arthritis in patients with positive anti-cyclic citrullinated peptide antibodies and undifferentiated arthritis SIR, The identification of baseline parameters that might predict the evolution of undifferentiated arthritis (UA) into RA is essential to initiate early therapy in patients. UA patients who have ACPAs are at high risk of developing RA.
We prospectively recruited 32 ACPA-positive UA patients in order to identify risk factors associated with progression to RA and/or development of bone erosion. The 2010 ACR/European League Against Rheumatism (EULAR) criteria were applied to our cohort. Sixty-eight patients with early RA (ERA) were analysed as a control group. The study was approved by the institutional review board (Commission d'é thique hospitalo-facultaire, Université Catholique de Louvain) and performed according to the Declaration of Helsinki. All patients provided written consent.
Baseline characteristics of ERA and UA patients are summarized in Table 1 . At baseline, UA patients had a mean of 6.4 (S.D. 4.7) tender joints and a mean of 2.8 (S.D. 1.5) swollen joints. The mean 28-joint DAS (DAS28)-CRP was 3.94 (S.D. 0.85). Hand and feet erosion were observed on the X-rays in three UA patients. After 1 and 2 years of follow-up, 13 (40.6%) and 22 (68.8%) UA patients, respectively, developed RA. Table 1 also shows the distribution of baseline characteristics in UA patients according to the development of RA or not after 2 years of follow-up (UA-RA, n = 22 vs UA-UA, n = 10). Mean tender joint count (TJC), swollen joint count (SJC), physician visual analogue scale (VAS) and serum CRP were lower in UA-UA compared with UA-RA patients, but the differences are not significant. Intriguingly, the MRI erosive pattern was also not different in the two groups at baseline.
We attributed cut-off values for the baseline variables that yielded the best sensitivity and specificity for the determination of two outcomes: having a diagnosis of RA after 2 years of follow-up and having X-ray visible erosion after 2 years (serum CRP >0.7 mg/dl, HAQ >1/3, DAS28-CRP >3.53, physician VAS >25 mm and patient VAS >50 mm). No statistical relationship was found between the chosen parameters and the endpoints.
For each patient at baseline, the 2010 ACR/EULAR classification criteria score for RA was calculated and compared with the diagnosis after the follow-up period. At baseline, 28 (87.5%) UA patients included had a score 56 or erosion at baseline. After 2 years of follow-up, among the 22 UA patients who developed RA, 19 fulfilled the criteria (sensitivity 86%). Nine of the 10 UA patients who did not develop RA did fulfil these criteria at baseline (specificity 10%).
Our study confirms that ACPA-positive UA patients are at a high risk of developing RA, since 13 of 32 patients (40.6%) met the 1987 ACR criteria for RA after 1 year and 68.8% (22/32) met the criteria after 2 years. However, due to the limited number of patients, the baseline ACR core set parameters were not significant. Interestingly, the presence of MRI baseline erosion was also not associated with the diagnosis of RA.
The presence of X-ray-visible erosion is a typical characteristic of RA [1], leading to the initiation of DMARD therapy. We therefore included this parameter as an endpoint in our study. However, we could not find any baseline parameter that was significantly associated with the development of erosion in our population.
At the time of study design, the primary outcome in the follow-up of the cohort was based on fulfilment of the 1987 ACR classification criteria [2] . These criteria were created to classify patients with long-standing disease and have been shown to be poorly sensitive in ERA [3] . Liao et al. [3] showed that adding ACPA positivity to the modified 1987 ACR criteria in early arthritis resulted in an increase in sensitivity from 25% to 63%. New ACR/ EULAR scores for the diagnosis of ERA have recently been validated, and also include ACPAs [4] . Bykerk et al. [5] recently highlighted the fact that the 2010 criteria had, besides high sensitivities, specificities that ranged between 50% and 80%. In our UA cohort, the 2010 ACR-EULAR criteria were very sensitive, but less specific, since 9 of the 10 UA patients who did not develop RA, and were in spontaneous remission after 2 years, fulfilled these criteria at baseline. Yet, implementation of these new criteria in daily practice will totally revisit the concept of UA since it will greatly decrease the number of patients with arthritis classified as UA. In addition, it appears that the 2010 ACR-EULAR criteria, while sensitive, lack specificity, with nearly 31.2% not developing definable disease over 2 years.
The main limitations of our study are the small sample size of the population and the higher probability of this population developing RA. However, this is the first attempt to select only ACPA-positive UA patients in order to evaluate the presence of predictive factors for the development of RA. Further studies will be needed in order to identify clinically relevant markers that will help clinicians tailor their diagnostic and therapeutic decisions.
Rheumatology key message
. Patients with undifferentiated arthritis and ACPAs are at high risk of developing RA. clinical disease activity index; SDAI: simplified disease activity index. The 68 ERA patients have significantly higher SJC, TJC, HAQ, CRP, patient global activity VAS, physician VAS, CDAI, SDAI, DAS28-CRP and erosion at baseline compared with the 32 UA patients using the MannWhitney U test (P < 0.05). Within the UA population, mean TJC, SJC, VAS physician, serum CRP, erosive MRI pattern or presence of bone erosion did not show any significant difference between the 10 UA-UA and 22 UA-RA patients using the MannWhitney U test (P < 0.05).
